Healthcare Business

Gritstone pushed higher on Tuesday after the company reported that it was advancing the development of a second-generation vaccine against SARS-CoV-2.
Aclaris shares more than doubled to start out the week after the company announced positive results from its mid-stage rheumatoid arthritis study.
Lexicon Pharma shares jumped on Thursday morning after the company announced that it received regulatory feedback from the FDA regarding its heart failure treatment.
UnitedHealth Group has agreed to pay about $7.8 billion in cash and assume some $5 billion in debt to acquire Change Healthcare, a competing provider of back-office services for health care providers.
Health care provider Centene has struck a deal to acquire Magellan Health in a transaction valued at $2.2 billion. Magellan is a leading provider of behavioral health programs.
Arcturus Therapeutics shares took a tumble on Tuesday after the company announced update on its COVID-19 vaccine candidate.
These are five top picks for 2021 from Jefferies for investors looking to add health care stocks to their portfolios. Many across Wall Street feel that the sector will continue to remain strong in...
Aprea Therapeutics stock was absolutely crushed to start out the week after the company announced results from its late-stage trial evaluating the safety and efficacy of its treatment for...
Myovant shares shot up on Monday after the company announced a new collaboration with Pfizer for its tumor treatment across a couple of indications.
Altimmune shares dropped on Thursday after the company announced that it had received an update from the FDA regarding its COVID-19 vaccine candidate.
Rates of both confirmed and fatal COVID-19 cases are highly uneven across the nation. The county with the worst rate of fatal cases remains Jerauld County, South Dakota.
Agios Pharmaceuticals shares jumped on Monday after the company announced that it will be streamlining its portfolio.
A new Stifel research report includes the firm's biotech stock picks for 2021. These five have the biggest upside to the posted price targets and are best suited for patient, aggressive growth...
These four sizzling biotech stocks trading under the $10 level could provide investors with some solid upside potential. They are all Buy rated at Goldman Sachs, one of the top firms on Wall Street.
The spread of COVID-19 and the number of fatal cases vary widely from state to state. New Jersey and North Dakota are among those states hit hard.